177746-81-5

Basic information

• Product Name: N-β-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine
• CAS NO: 177746-81-5
• Molecular Weight: 573.581
• Mol File: 177746-81-5.mol

Chemical Properties

• CAS DataBase Reference: N-β-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine(CAS DataBase Reference)
• NIST Chemistry Reference: N-β-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine(177746-81-5)
• EPA Substance Registry System: N-β-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine(177746-81-5)

Safety Data

• Hazardous Substances Data: 177746-81-5(Hazardous Substances Data)

Upstream product

• 70-18-8 GLUTATHIONE 
• 21612-39-5 β-alanyl-L-dopa 

Relevant articles and documents

Inhibition effects of 5-S-glutathionyl-N-β-alanyl-L-dopa analogues against Src protein tyrosine kinase

Twelve analogues of the antibacterial phenolic peptide 5-S- glutathionyl-N-β-alanyl-L-dopa (5-S-GA-L-D, 1) were synthesized via orthoquinone using tyrosinase. Several synthesized compounds inhibited the v- Src autophosphorylation tyrosine kinase reaction with an IC50 value comparable to that of herbimycin A. The inhibition of c-Src substrate phosphorylation was much less active than v-Src autophosphorylation inhibition. 5-S-GAL-D (1) and its analogous competed with peptide substrate and non-competed with ATP. The analogues showed no effects on substrate phosphorylation by epidermal growth factor receptor (EGFR), and this selectivity is the most characteristic feature of the 5-S-GA-L-D and its analogues (1 - 12).

Selective inhibition of Src protein tyrosine kinase by analogues of 5- S-glutathionyl-β-alanyl-L-dopa

Twelve analogues of the antibacterial phenolic peptide 5-S- glutathionyl-β-alanyl-L-dopa (5-S-GA-L-D: 1) were synthesized via orthoquinones using tyrosinase. Several synthesized compounds inhibited the v-Src autophosphorylation tyrosine kinase reaction with an IC50 value comparable to that of herbimycin. The inhibition of c-Src substrate phosphorylation was much less active than v-Src autophosphorylation inhibition. The analogues showed no effects on substrate phosphorylation by epidermal growth factor receptor (EGFR), and this selectivity is the most characteristic feature of the analogues (1-12).